Cervix Cancer, Dysplasia, Papillomavirus Infections
Conditions
Keywords
Matrix metalloproteinases
Brief summary
This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.
Detailed description
Cervical cancer is the second most common cancer among European women under 45 years old. It is secondary to cervical dysplasia induced by persistent human papillomavirus infection. The involvement of matrix metalloproteinases in carcinogenesis of the cervix is real, but their expressions vary according to the published series. An association between the expression of MMPs and that of the human papillomavirus deserves to be explored, as this can have a prognostic influence in the case of gradual expression demonstrated in the development of (pre) cancerous lesions of the cervix. This study aims to compare the expression of matrix metalloproteinases and their tissue inhibitors between 4 groups of patients defined according to the severity of the cervical lesion.
Interventions
OTHERVaginal samples (biopsies + vaginal smear)
Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
Sponsors
University Hospital, Bordeaux
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
For control group: * Age between 20 and 65 years * Patients hospitalized for partial or total removal of the cervix * Absence of cervical lesion observed on biopsy or hysterectomy * Free, informed and written consent, dated and signed by the patient and the investigator (at the latest before any examination required by the study) * Affiliate or beneficiary of a social security scheme For dysplasia and cancer group: * Age between 20 and 65 years * Cervical Intraepithelial Neoplasia or previously untreated cervical cancer * Free, informed and written consent, dated and signed by the patient and the investigator (at the latest before any examination required by the study) * Affiliate or beneficiary of a social security scheme
Exclusion criteria
For control group: * History of laser or conisation * Known antecedent of HIV infection * Congenital or acquired immunodepression * Long-term treatment with corticosteroids or immunosuppressants * Persons placed under the protection of justice For dysplasia and cancer group: * History of laser or conisation * Pre-treatment of invasive cancers by radiotherapy or chemotherapy * Known antecedent of HIV infection * Congenital or acquired immunodepression * Long-term treatment with corticosteroids or immunosuppressants * Persons placed under the protection of justice
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunohistochemical score of expressions of matrix metalloproteinases | At the screening | The immunohistochemical score is the modified HScore, also called Quickscore. It is calculated by multiplying the percentage of cells that are marked (from 0 to 100) by intensity (from 0 to 3). The total score is between 0 and 300. This score will be defined on normal, tumoral and stromal cells according to the analyzed tissue (normal, dysplasias or cancer) |
| Immunohistochemical score of expressions of matrix metalloproteinases inhibitors | At the screening | The immunohistochemical score is the modified HScore, also called Quickscore. It is calculated by multiplying the percentage of cells that are marked (from 0 to 100) by intensity (from 0 to 3). The total score is between 0 and 300. This score will be defined on normal, tumoral and stromal cells according to the analyzed tissue (normal, dysplasias or cancer) |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORJean-Luc BRUN, Dr
University Hospital, Bordeaux
Outcome results
None listed